证券代码：688177 证券简称：百奥泰 公告编号：2026-007 百奥泰生物制药股份有限公司 关于变更保荐代表人的公告 特此公告。 百奥泰生物制药股份有限公司董事会 2026年2月3日 保荐代表人李胤康先生简历 李胤康先生，A股保荐代表人，金融学硕士，现就职于中金公司投资银行部。曾参与或主持包括恒润达 生科创板IPO、泽璟制药科创板增发、怡和嘉业创业板IPO、诺诚健华科创板IPO、华厦眼科创业板 IPO、悦康药业科创板IPO、大博医疗中小板IPO、现代制药重大资产重组、步长制药主板IPO等项目， 在保荐业务执业过程中严格遵守《证券发行上市保荐业务管理办法》等相关规定，执业记录良好。 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于2026年2月2日收到中国国际金融股份有 限公司（以下简称"中金公司"）《关于更换百奥泰生物制药股份有限公司持续督导保荐代表人的说 明》。中金公司作为公司首次公开发行股票并在科创板上市项目的保荐机构，原委派孔德进先生和任孟 琦先生担任公司持续督导期的保荐代表人。现因保荐代表人孔德进先生工作变动，不再担任百奥泰的持 续督导保荐代表人。 为保证公司持续督导工作的正常进行， ...

Core Viewpoint - Double-Helix Pharmaceutical (002038) is expected to continue incurring losses in 2025, with a projected net profit loss of between -200 million to -290 million yuan, representing a year-on-year decline of 170.03% to 291.54% [3][4] Group 1: Financial Performance - The company reported a net profit loss of approximately -74.07 million yuan in 2024, marking a shift from profit to loss [3] - The expected non-recurring losses for 2025 are estimated to reduce net profit by about 200 million yuan, significantly impacting overall financial performance [5] - The sales revenue for 2024 was approximately 660 million yuan, a year-on-year decrease of 35.15% [3] Group 2: Sales and Margins - Sales gross margin decreased by about 10% due to a decline in product prices, which was influenced by centralized procurement policies [4] - The company's major product line, anti-tumor and immune regulation products, generated sales of 276 million yuan, accounting for 42.69% of total sales, with a year-on-year decline of 27.69% [4] Group 3: Investment and Financial Losses - The company faced significant investment losses, particularly from financial assets, which have become a critical factor affecting its performance [6] - Chairman Xu Mingbo has voluntarily committed to cover the irrecoverable portion of investment losses, with an initial payment of 50 million yuan to the company [5] Group 4: Strategic Response - The company plans to accelerate the launch of new products and strengthen its marketing network to adapt to changes in the pharmaceutical market due to procurement policies [5]

Group 1 - Day One Biopharmaceuticals, Inc. (DAWN) closed at $11.16, reflecting a 26.1% gain over the past four weeks, with a mean price target of $22.44 indicating a potential upside of 101.1% [1] - The average price target ranges from a low of $16.00 to a high of $29.00, with a standard deviation of $4.59, suggesting a variability in analyst estimates [2] - Analysts have shown increasing optimism regarding DAWN's earnings prospects, as indicated by a positive trend in earnings estimate revisions, with a 20.6% increase in the Zacks Consensus Estimate for the current year [11][12] Group 2 - DAWN currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - The clustering of price targets with a low standard deviation indicates a high degree of agreement among analysts about the stock's price movement direction [9] - While price targets should not be the sole basis for investment decisions, they can provide a useful guide for potential price movement [14]

Core Viewpoint - The HPV vaccine market is experiencing a decline in growth, leading to significant financial challenges for major companies like Zhifei Biological, Wantai Biological, and Watson Biological, with all three facing operational difficulties and inventory pressures [1][3][6]. Financial Performance - Zhifei Biological is projected to incur a net loss of 10.698 billion to 13.726 billion yuan in 2025, marking a staggering decline of 630% to 780% year-on-year [3][6]. - Wantai Biological anticipates its first annual net loss since going public, estimated between 330 million to 410 million yuan [3][6]. - Watson Biological expects a net profit of 160 million to 190 million yuan in 2025, reflecting a year-on-year growth of 13% to 34% [3][6]. Inventory Challenges - Zhifei Biological faces an inventory burden exceeding 20 billion yuan, with a significant portion of its nine-valent vaccines set to expire in 2026 [4][5]. - Wantai Biological's two-valent vaccine sales are hindered by market competition and near-expiry inventory, leading to a decline in sales [6][7]. Market Dynamics - The HPV vaccine market is shifting from a phase of high demand to one characterized by increased competition and price wars, compelling companies to adapt their strategies from "price for volume" to "quality for breakthrough" [1][9]. - The introduction of new vaccines, including Wantai's nine-valent vaccine, has intensified competition, but market acceptance remains slow [7][11]. Pricing Strategies - The price of Wantai's two-valent HPV vaccine has drastically decreased from 329 yuan to 27.5 yuan due to public procurement initiatives, reflecting a more competitive pricing environment [10][11]. - Watson Biological's two-valent vaccine is also priced at 27.5 yuan under the national immunization program, indicating a significant reduction from its initial pricing [10][11]. Future Outlook - Companies are exploring various strategies to optimize operations, including adjusting procurement plans, enhancing product promotion, and improving inventory turnover [5][8]. - Experts suggest that overcoming the current challenges requires a focus on technological upgrades, brand building, and international expansion rather than solely competing on price [11].

（文章来源：证券日报） 证券日报网讯 2月2日，万泰生物在互动平台回答投资者提问时表示，截至目前，公司没有尼帕病毒检 测试剂生产。公司有相关产品技术储备，将根据疫情和市场需要启动。 ...

公告指出，受行业政策持续深化及公司核心产品安佳因 多次降价影响，核心产品销售收入降幅较大， 致使公司整体营业收入较上年同期下降。此外，公司相应加大了前期商业化投入，包括学术推广、组建 销售团队等，销售费用因此在短期内增幅明显，而且公司研发投入继续保持高位，影响当期盈利表现。 近日，神州细胞发布公告称，公司预计2025年归母净亏损5.2亿元至5.8亿元；预计扣非净亏损5.03亿元 至5.63亿元；预计公司2025年度研发投入为8.3亿元到8.7亿元。 ...

Core Viewpoint - Da An Gene (002030) expects a net profit loss attributable to shareholders of approximately 607 million to 865 million yuan for the fiscal year 2025, showing improvement compared to a loss of 925 million yuan in the same period last year [1] Group 1: Financial Performance - The main reasons for the performance change include a decrease in operating revenue due to market demand and adjustments in the value-added tax rate for self-produced reagent products [1] - The company has implemented various cost-saving measures to enhance operational efficiency, but the fixed costs such as operational and labor costs remain high, making it difficult for the revenue decline to match the cost reduction in the short term, negatively impacting the overall gross profit [1] Group 2: Investment and Earnings - During the reporting period, the performance of the company's joint ventures improved compared to the previous year, leading to an increase in investment income recognized from joint ventures [1] - The net profit attributable to shareholders of the listed company increased compared to the same period last year [1]

Core Viewpoint - Chengda Biological announced that it did not implement any share repurchase in January 2026, with a total of 384,899 shares repurchased by January 31, 2026, representing approximately 0.092% of the company's total share capital [1] Summary by Category - **Share Repurchase Activity** - The company has repurchased a total of 384,899 shares through the Shanghai Stock Exchange trading system via centralized bidding [1] - The repurchased shares account for about 0.092% of the company's total share capital as of January 31, 2026 [1]

证券日报网讯2月2日，艾德生物（300685）发布公告称，截至2026年1月31日，公司通过回购专用证券 账户以集中竞价交易方式实施回购股份696，400股，占公司目前总股本的0.18%，回购股份的最高成交 价为22.16元/股，最低成交价为20.50元/股，支付的总金额为14，990，827.10元(不含交易费用)。 ...

Core Viewpoint - The HPV vaccine market is experiencing a significant downturn, with major companies facing operational challenges and financial losses as they transition from rapid growth to a more competitive landscape [1][2]. Group 1: Company Performance - Zhifei Biological is projected to incur a net loss of 10.698 billion to 13.726 billion yuan in 2025, marking a staggering decline of 630% to 780% year-on-year [4][6]. - Wantai Biological anticipates its first annual net loss since going public, estimated between 330 million to 410 million yuan [4][2]. - Watson Biological expects a net profit of 160 million to 190 million yuan in 2025, reflecting a year-on-year growth of 13% to 34%, although its net profit excluding non-recurring items is projected to decline by 9% to 22% [2][4]. Group 2: Market Dynamics - The HPV vaccine market is facing intense competition, leading to price wars as companies attempt to gain market share amid declining demand and increasing product homogeneity [1][8]. - Zhifei Biological is burdened with over 20 billion yuan in inventory, with a significant portion of its nine-valent vaccines set to expire in 2026, raising concerns about potential write-offs [7][8]. - Wantai Biological's sales of its bivalent vaccine have been adversely affected by the approval of competing products and the expansion of the nine-valent vaccine's age range, leading to a sharp decline in revenue and profit [8][9]. Group 3: Strategic Responses - Companies are adjusting their strategies to cope with market pressures, including optimizing procurement plans, enhancing product promotion strategies, and improving inventory turnover efficiency [7][16]. - Wantai Biological and Watson Biological are targeting the public procurement market to stabilize their positions, with significant price reductions for their bivalent vaccines [12][15]. - The industry is urged to shift from a price-driven approach to one focused on quality, technological upgrades, brand building, and international expansion to overcome current challenges [16].